Iranian Journal of Pediatrics

Published by: Kowsar

NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy

Hala Mahmoud Koura 1 , * , Neamat M. Abdalla 2 , Mona Hamed Ibrahim 3 , Maha M. A. Abo Hashish 1 and Sherif Mohamed Zaki 4
Authors Information
1 Department of Pediatrics, National Research Center, Cairo, Egypt
2 Atfal Misr Hospital, Cairo, Egypt
3 Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
4 Faculty of Medicine, Cairo University, Cairo, Egypt
Article information
  • Iranian Journal of Pediatrics: June 2016, 26 (3); e4485
  • Published Online: May 15, 2016
  • Article Type: Research Article
  • Received: October 23, 2015
  • Revised: January 2, 2016
  • Accepted: January 23, 2016
  • DOI: 10.5812/ijp.4485

To Cite: Koura H M, Abdalla N M, Hamed Ibrahim M, Abo Hashish M M A, Zaki S M. et al. NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy, Iran J Pediatr. 2016 ;26(3):e4485. doi: 10.5812/ijp.4485.

Abstract
Copyright © 2016, Growth & Development Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
References
  • 1. Cowie MR, Mendez GF. BNP and congestive heart failure. Progress Cardiovasc Dis. 2002; 44(4): 293-321
  • 2. Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta. 2004; 349(1-2): 25-38[DOI][PubMed]
  • 3. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001; 47(5-6): 265-77[PubMed]
  • 4. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003; 4(2): 72-80[PubMed]
  • 5. Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem. 2004; 50(9): 1670-2[DOI][PubMed]
  • 6. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998; 135(5 Pt 1): 825-32[PubMed]
  • 7. Cheung BM. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol. 1997; 24(12): 966-8[PubMed]
  • 8. Baughman KL. B-type natriuretic peptide -- a window to the heart. N Engl J Med. 2002; 347(3): 158-9[DOI][PubMed]
  • 9. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003; 45(3): 249-54[PubMed]
  • 10. Kavga M, Varlamis G, Giannopoulos A, Papadopoulou-Legbelou K, Varlamis S, Bompotis G, et al. Correlation of plasma B-type natriuretic peptide with shunt volume in children with congenital heart disease involving left-to-right shunt. Hellenic J Cardiol. 2013; 54(3): 192-8[PubMed]
  • 11. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141(3): 367-74[DOI][PubMed]
  • 12. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JJ. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40(5): 976-82[PubMed]
  • 13. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002; 90(3): 254-8[PubMed]
  • 14. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr. 2004; 93(3): 340-5[PubMed]
  • 15. Driscoll DJ. 2013 College of Diplomates of the American Board of Pediatric Dentistry Annual Meeting: pediatric cardiology: an overview. Pediatr Dent. 2013; 35(5)-47[PubMed]
  • 16. Tighe JJ, Steiman DM, Vernalis MN, Taylor AJ. Observer bias in the interpretation of dobutamine stress echocardiography. Clin Cardiol. 1997; 20(5): 449-54[PubMed]
  • 17. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002; 105(5): 595-601[PubMed]
  • 18. Kayar A, Gonul R, Or ME, Uysal A. M-mode echocardiographic parameters and indices in the normal German shepherd dog. Vet Radiol Ultrasound. 2006; 47(5): 482-6[PubMed]
  • 19. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther. 2009; 3: 269-87[PubMed]
  • 20. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J. 1996; 17(11): 1694-702[PubMed]
  • 21. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005; 91(5): 606-12[DOI][PubMed]
  • 22. Davis GK, Bamforth F, Sarpal A, Dicke F, Rabi Y, Lyon ME. B-type natriuretic peptide in pediatrics. Clin Biochem. 2006; 39(6): 600-5[DOI][PubMed]
  • 23. Cantinotti M, Passino C, Storti S, Ripoli A, Zyw L, Clerico A. Clinical relevance of time course of BNP levels in neonates with congenital heart diseases. Clin Chim Acta. 2011; 412(23-24): 2300-4[DOI][PubMed]
  • 24. Cantinotti M, Clerico A, Murzi M, Vittorini S, Emdin M. Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. Clin Chim Acta. 2008; 390(1-2): 12-22[DOI][PubMed]
  • 25. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43(4): 635-41[DOI][PubMed]
  • 26. Auerbach SR, Richmond ME, Lamour JM, Blume ED, Addonizio LJ, Shaddy RE, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail. 2010; 3(5): 606-11[DOI][PubMed]
  • 27. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001; 37(2): 379-85[PubMed]
  • 28. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002; 106(4): 416-22[PubMed]
  • 29. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998; 351(9095): 9-13[PubMed]
  • 30. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995; 26(7): 1565-74[DOI][PubMed]
  • 31. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998; 31(1): 202-8[PubMed]
  • 32. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132(6): 425-34[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments